Published in Medical Letter on the CDC and FDA, June 11th, 2000
[helv] SmithKline Beecham fully supports the Food and Drug Administration's position that the newer thiazolidinediones, more commonly known as glitazones, including Avandia, are valuable alternatives for patients with type 2 diabetes.
Almost one year ago, the Committee reviewed the comprehensive efficacy and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA